Although non-drugs are currently in clinical trials for the treatment of patients with asporin dysregulation cancers, there are several potential strategies to reduce asporin functional dose in future cancer studies: (1) inhibition of asporin protein-protein interactions; (2) targeting asporin mRNA. Here, ASPN is linked to cancer.